New Pill for Scarred-Lung Disease in Adults

Who this is for

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, the United Kingdom and the European Union, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed. In Canada, authorisation is not confirmed; see Possible routes below if any are listed.

Ways to access this treatment

• United States · Prescription

  US prescription (FDA-labelled)

  https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fa1b14c6-957f-d326-5099-911bfe33e391

• United Kingdom · Prescription

  UK prescription (MHRA-authorised)

  https://www.gov.uk/government/news/nerandomilast-jascayd-approved-to-treat-adult-patients-with-idiopathic-pulmonary-fibrosis-and-progressive-pulmonary-fibrosis

• European Union · Prescription

  EU prescription (EC marketing authorisation)

  https://www.ema.europa.eu/en/medicines/human/EPAR/jascayd

• United States, United Kingdom, European Union, Canada · Recruiting clinical trial

  FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

  Tests this treatment. Nerandomilast vs placebo in fibrosing ILD (FIBRONEER-ACT, phase 3).

  https://clinicaltrials.gov/study/NCT07540988

• United States, United Kingdom, European Union, Canada · Recruiting clinical trial

  A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

  Combination or different setting. Relatives with interstitial lung abnormalities (prevention setting), not established IPF/PPF (phase 3).

  https://clinicaltrials.gov/study/NCT07201922

• United States, United Kingdom, European Union, Canada · Recruiting clinical trial

  A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

  Combination or different setting. Children and adolescents 2-17 with fibrosing ILD; the label is adults (phase 3).

  https://clinicaltrials.gov/study/NCT07366034

Search all trials on ClinicalTrials.gov: https://clinicaltrials.gov/search?cond=interstitial%20lung%20disease&intr=nerandomilast&aggFilters=status:rec

Search Health Canada's Clinical Trials Search Portal: https://clinical-trials-search.canada.ca/en/search?search_api_fulltext=nerandomilast

Possible routes (not confirmed)

• Canada · Health Canada Special Access Programme (SAP) · Applicability unknown

  Health Canada Special Access Programme (manufacturer must agree)

  SAP here depends on the manufacturer agreeing to supply; no confirmation for this drug.

  https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/drugs.html

General resources for further research

• Canadian Clinical Trial Search Portal (Health Canada)

  Health Canada's public search of the drug and biologic clinical trials it has authorised in Canada (phase 1 to 3, since April 2013). Search by condition, drug, or trial status and see where trials are running. It replaced the Health Canada Clinical Trials Database in July 2026. A listing is not enrolment, and Health Canada does not recruit patients: ask your clinician and contact the trial sponsor.

  https://clinical-trials-search.canada.ca/en/home

• ClinicalTrials.gov

  US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.

  https://clinicaltrials.gov/

• CTIS (EU Clinical Trials Information System)

  European Union public portal for clinical trials submitted under the Clinical Trials Regulation. Search by medicine, condition, and member state. A CTIS record is not an EMA marketing authorisation and is not enrolment.

  https://euclinicaltrials.eu/